<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970034</url>
  </required_header>
  <id_info>
    <org_study_id>108S375</org_study_id>
    <nct_id>NCT00970034</nct_id>
  </id_info>
  <brief_title>Gene Expression Profiles in Patients With Permanent Atrial Fibrillation (AF) Versus Sinus Rhythm (SR)</brief_title>
  <official_title>Comparative Gene Expression Profiles in Patients With Permanent Atrial Fibrillation and Normal Sinus Rhythm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tubitak</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ankara University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to determine the morphological criteria of apoptosis in atrial
      tissues of patients with AF versus SR at transcriptome and genomic size.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mitral valve regurgitation (MR) is the second most common valvular heart disease encountered
      in adults. Furthermore, atrial fibrillation (AF) is the most common cardiac arrhythmia seen
      in clinical practice. Overall, 70% of the patients with severe MR are associated with AF
      independent from etiopathogenesis of MR. AF is clinically divided into three subgroups; 1)
      paroxysmal AF, occurs as episodes and ends spontaneously, 2) persistent AF, episodes
      terminate only with medical or electrical cardioversion, and 3) permanent AF, current medical
      treatments and electrical cardioversion does not restore a normal sinus rhythm. Despite
      intensive electrophysiological studies, the molecular mechanisms and pathways of AF are still
      not fully elucidated.

      Apoptosis which has distinctive morphological and biochemical characteristics is genetically
      regulated, active programmed cell death process. It is known that cardiac morphogenesis
      restore from apoptosis. In addition, apoptosis has an important role in several
      cardiovascular system pathologies. It has been shown that atrial apoptosis causes numerous
      arrhythmias including AF. Likewise, in the pilot study which has been performed by our study
      group, AF is associated with apoptosis by immunohistochemical and DNA fragmentation analysis
      methods.

      The aim of this project is to determine the morphological criteria of apoptosis in atrial
      tissues of patients with AF by using electron microscopy and immunohistochemistry. Moreover,
      we will investigate the transcriptional profile of AF associated genes by oligonucleotide
      microarray method. The gene expression profiles of patients with AF and degenerative MR will
      be compared with the atrial tissue samples from the patients with degenerative MR who
      preserve normal sinus rhythm which will serve as controls. In summary the apoptotic pathways
      would be analyzed at transcriptomic and genomic level. Besides, the pathways that may
      interfere AF pathophysiology would also be evaluated. The expression profiles of the genes
      primarily verified by quantitative real time RT-PCR will be further confirmed by translation
      of end-result proteins determined with Western blot technique. Thus, brand-new clues about
      physiology of fibrillating atrial cells would be achieved.

      Keywords: Atrial fibrillation, apoptosis, oligonucleotide microarray
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression profiles of genes related to apoptosis</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression profiles of pro-apoptotic and anti-apoptotic proteins</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Sinus Rhythm</condition>
  <arm_group>
    <arm_group_label>AF</arm_group_label>
    <description>Patients with degenerative mitral valve regurgitation and permanent atrial fibrillation who require mitral valve repair or replacement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SR</arm_group_label>
    <description>Patients with degenerative mitral valve regurgitation and maintaining sinus rhythm who require mitral valve repair or replacement.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Human atrial tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Degenerative mitral valve regurgitation who require cardiac valve surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with permanent atrial fibrillation or sinus rhythm and degenerative mitral
             valve regurgitation who require cardiac surgery

          -  Pulmonary hypertension (systolic PA &gt; 45 mmHg)

          -  Left ventricular ejection fraction &gt; 30%

        Exclusion Criteria:

          -  Paroxysmal AF or atrial flutter

          -  Second or third degree heart block

          -  Permanent pacemaker

          -  Wolff-Parkinson-White syndrome

          -  Brugada syndrome

          -  Ischemic or rheumatic mitral valve disease

          -  Dilated cardiomyopathy

          -  LVEF &lt; 30%

          -  Infective endocarditis, myocarditis

          -  Trauma

          -  Active HBV, HCV, HIV infection

          -  Chronic renal failure

          -  Autoimmune diseases

          -  Vasculitis

          -  Known genetic disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RUCHAN A AKAR, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RUCHAN AKAR, Assoc. Prof.</last_name>
    <phone>+905336460684</phone>
    <email>akarruchan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HILAL OZDAG, Assoc. Prof.</last_name>
    <phone>+905333717401</phone>
    <email>hilalozdag@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ankara University Medical Faculty, Department of Cardiovascular Surgery,</name>
      <address>
        <city>Ankara</city>
        <zip>06340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUNSELI CUBUKCUOGLU</last_name>
      <phone>+905336424994</phone>
      <email>gunselicubukcu@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>SERKAN DURDU</last_name>
      <phone>+905336373535</phone>
      <email>serkandurdu@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>RUCHAN A AKAR, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>HILAL OZDAG, Assoc. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ARZU ATALAY, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>NALAN AKYUREK, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>HAKAN GURDAL, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>OMER AKYUREK, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>UMIT OZYURDA, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>GUNSELI CUBUKCUOGLU, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SERKAN DURDU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CAGIN ZAIM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <last_update_submitted>September 2, 2009</last_update_submitted>
  <last_update_submitted_qc>September 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>A. Ruchan Akar, Assoc. Prof.</name_title>
    <organization>Ankara University</organization>
  </responsible_party>
  <keyword>Atrial fibrillation, apoptosis, oligonucleotide microarray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

